Clinical trials: Coronavirus Infections
COVID-19, Influenza
Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
This study is an open-label, single-center, randomized phase IV clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04801888
- Testing
- Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
SARS-CoV-2 Infection
Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.
This is a phase II/III parallel, double-blind, active-controlled, non-inferiority study to evaluate immunogenicity and safety of a booster immunization scheme of a single intramuscular dose of the recombinant vaccine against…
- Trial name
- NCT05710783
- Testing
- AVX-COVID/12, ChAdOx-1-S[recombinant]
- Where
- 14 sites in Mexico
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID-19
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to…
- Trial name
- NCT05003479
- Testing
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04623021
- Testing
- Nafamostat Mesilate
- Where
- 11 sites in Russia
- Volunteers
- 104 people
- Sponsor
- Chong Kun Dang Pharmaceutical
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
Pneumonia, Viral
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
- Trial name
- NCT04878055
- Testing
- Reparixin
- Where
- 17 sites in United States, Italy
- Volunteers
- 287 people
- Sponsor
- Dompé Farmaceutici S.p.A
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
This is a study to evaluate the effectiveness and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in a minimum of approximately 2,960 to a maximum of approximately 4,164…
- Trial name
- NCT04533399
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant
- Where
- 14 sites in South Africa
- Volunteers
- 4,422 people, healthy volunteers welcome
- Sponsor
- Novavax
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
COVID-19
A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001
This is a randomized, double-blind, placebo-controlled Phase Ⅰ trial in healthy adults aged 18 years and older, intended to evaluate the safety, reactogenicity, and immunogenicity profile of LYB001.
- Trial name
- NCT05125926
- Testing
- LYB001
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
COVID-19 Vaccines
The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind study designed to evaluate the safety, immunogenicity and efficacy of ARCT-154 in adult participants to be enrolled in Vietnam.
- Trial name
- ARCT-154-01 (NCT05012943)
- Testing
- ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Astra Zeneca COVID-19 vaccine
- Where
- 3 sites in Vietnam
- Volunteers
- 19,474 people, healthy volunteers welcome
- Sponsor
- Vinbiocare Biotechnology Joint Stock Company
Covid19, Corona Virus Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
- Conditions
- Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection
- Trial name
- NEUROSIVIR (NCT04480333)
- Testing
- Drug: NA-831 - 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Biomed Industries, Inc.
Covid19
Detection of COVID-19 Using Breath Analysis - Validation Study
DETECTION OF THE 2019 NOVEL CORONAVIRUS (SARS-CoV-2) USING BREATH ANALYSIS- VALIDATION STUDY
- Trial name
- COVID-19 (NCT04602949)
- Testing
- Breath Biopsy Analysis
- Where
- Israel
- Volunteers
- 2,558 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
Covid19, Corona Virus Infection
SPI-1005 Treatment in Moderate COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19…
- Conditions
- Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection
- Trial name
- NCT04484025
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Moderate to Severe COVID-19
Efficacy and Safety of JT001 (VV116) Compared With Favipiravir
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) for the Treatment of Coronavirus Disease 2019 (COVID-19) in participants with moderate to severe COVID-19.
- Trial name
- NCT05279235
- Testing
- JT001, Favipiravir
- Where
- 2 sites in China, Uzbekistan
- Volunteers
- 290 people
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04299152
- Testing
- Stem Cell Educator-Treated Mononuclear Cells Apheresis
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Coronavirus Infection
Covid-19, Hospitalized, PatIents, Nasafytol
The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital…
- Trial name
- NCT04844658
- Testing
- NASAFYTOL®, FULTIUM® -D3 800, Strandard of care treatment
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Tilman S.A.
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Coronavirus Disease 2019 (COVID-19)
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and immunogenicity of AK119, a humanized monoclonal…
- Trial name
- NCT04516564
- Testing
- AK119
- Where
- New Zealand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.